HDFC: 14% in 5 years. Small-cap: 200%. Which would you hold?

titan biotech stock volatile chart

Investment paradox I’m observing:

HDFC Bank: 14% returns (5 years)
Infosys: 0% returns (5 years)…excluding dividends.

Investors hold these comfortably.

Small-cap that delivers 200% net return (after – 40% drawdown first):

Same investors panic-sell at the bottom.

Why? It’s not about returns. It’s about emotional comfort.

Let me share with you The Psychology of “Comfortable Underperformance”. Before that:

Help us grow: If our research adds value to your investing process, we’d appreciate you spreading the word about Katalyst Wealth to friends, family, or colleagues who might benefit.

 

Important updates on New recommendations:

  • For Alpha/Alpha + members – On 22nd Mar’26, we released a new long term investment recommendation for (opens in new tab)Alpha and Alpha + members. Company has a Strong niche in rail‑centric infra (bridges, sleepers, signalling) with a large order book and strong balance sheet with good multi‑year growth visibility. Current mid‑teens P/E provide strong margin of safety. You can access it by signing up (opens in new tab)HERE
  • For Insider Bets members – On 22nd Jan’26, we released our New stock report under (opens in new tab)Insider Bets subscription. It’s a rare setup wherein Promoter is increasing stake via open market + preferential allotment, Valuations very reasonable at <10x earnings | <1x book and Earnings growth strong at 15%+ CAGR. You can access it by signing up (opens in new tab)HERE

 

The Psychology of “Comfortable Underperformance”

Infy 5 years zero return
t

 

Holding HDFC or INFY for low returns feels safe, rational, socially acceptable.

Holding small-cap through – 40% feels scary, irrational, embarrassing.

Even if the small-cap eventually does 5x.

The Math:

Blue-chip: ₹100 → ₹114 (5 years) | Low volatility | Good sleep
Small-cap: ₹100 → ₹60 → ₹300 (5 years) | Extreme volatility | Terrible sleep (Year 1-2)

Which made more? Small-cap (by 13x).
Which is easier to hold? HDFC (by 100x).

The disconnect:

Returns measured in ₹.
Emotions measured in pain.

Most optimize for: Minimum pain > Maximum returns

The Brutal Truth:

Life-changing returns require:

  • Stomach for -40% drawdowns
  • Conviction through 2 years of volatility
  • Tolerance for looking wrong temporarily

Most investors SAY they want high returns.

Their behavior reveals: They want comfort + reasonable returns.

Nothing wrong with that. Just be honest.

The Framework:

Optimize for comfort:
Large-caps → 10-12% returns → Low volatility

Optimize for returns:
Small/mid-caps → 3-5x potential (or -50%) → Extreme volatility

You cannot have both.

The Question:

Can you handle 2 years at -40% while friends in blue chips “do fine”?

If yes: Volatile small-caps possible.
If no: Stick to large-caps/index.

Both valid. Just match portfolio to YOUR actual temperament.

Returns come from: (1) Picking stocks (2) Holding through volatility

Most focus on #1. Most fail at #2.

Know yourself. Build accordingly.

Not a subscriber?
We closely track promoter buying, preferential allotments and insider activity as part of our research process at (opens in new tab)Insider Bets. 6 new deeply researched ideas per year, quarterly earnings coverage, entry/exit guidance.
(opens in new tab)Learn more about Insider Bets →

Hope you found the blog post useful and it added value to your investment decisions. Sign up for more interesting stock ideas and industry notes.

 

 

Disclaimer: This is not a recommendation to buy/sell any of the stocks mentioned above. The securities quoted are for illustration only and are not recommendatory.

Ekansh Mittal
Research Analyst

 

SEBI Research Analyst Registration No. INH100001690
Research Analyst Details

Name: Ekansh Mittal     Email Id: (opens in new tab)[email protected]    Ph: +91 727 5050062

Details of Associate: Not Applicable

Analyst Certification: The Analyst certify (ies) that the views expressed herein accurately reflect his (their) personal view(s) about the subject security (ies) and issuer(s) and that no part of his (their) compensation was, is or will be directly or indirectly related to the specific recommendation(s) or views contained in this research report.

Disclaimer: (opens in new tab)http://www.katalystwealth.com (here in referred to as Katalyst Wealth) is the domain owned by Ekansh Mittal. Mr. Ekansh Mittal is the sole proprietor of Mittal Consulting and offers independent equity research services to investors on subscription basis. SEBI (Research Analyst) Regulations 2014, Registration No. INH100001690, BSE Enlistment No. 5114

Registered Address – 7, Panch Ratan, 7/128, Swaroop Nagar, Kanpur – 208002

Place of Business – 205, Ratan Floor, 113/120, Swaroop Nagar, Kanpur – 208002

Compliance Officer/Grievance Redressal – Mr. Ekansh Mittal, +91-9818866676, (opens in new tab)info@katalystwealth.com

“Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors”.

“Investment in securities market are subject to market risks. Read all the related documents carefully before investing.”

The views expressed are based solely on information available publicly and believed to be true. Investors are advised to independently evaluate the market conditions/risks involved before making any investment decision

This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. Ekansh Mittal/Mittal Consulting/Katalyst Wealth is not soliciting any action based upon it. This report is not for public distribution and has been furnished to you solely for your information and should not be reproduced or redistributed to any other person in any form. This document is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Ekansh Mittal or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Neither Ekansh Mittal, nor its employees, agents nor representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. Ekansh Mittal/Mittal Consulting or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement.

The recipients of this report should rely on their own investigations. Ekansh Mittal/Mittal Consulting and/or its affiliates and/or employees may have interests/ positions, financial or otherwise in the securities mentioned in this report. Mittal Consulting has incorporated adequate disclosures in this document. This should, however, not be treated as endorsement of the views expressed in the report.

We submit that no material disciplinary action has been taken on Ekansh Mittal by any regulatory authority impacting Equity Research Analysis.

Use of Artificial Intelligence: RA may infrequently use Artificial Intelligence (AI) tools like chatgpt, notebooklm, etc. in its research services to enhance the quality and efficiency of the recommendations provided to clients. The tools are primarily used for data collection and generating con-call summaries for the purpose of research.

In accordance with Regulation 24(7) of the SEBI (Research Analyst) Regulations, 2014: We take full responsibility for the security, confidentiality, and integrity of client data used in conjunction with AI tools and we ensure compliance with applicable laws regarding the use of AI tools.

Disclaimer: You can access it here – (opens in new tab)LINK

Whether the research analyst or research entity or his associate or his relative has any financial interest in the subject company/companies and the nature of such financial interest – Yes, in Titan Biotech

Whether the research analyst or research entity or his associates or his relatives have actual/beneficial ownership of 1% or more securities of the subject company (at the end of the month immediately preceding the date of publication of the research report or date of the public appearance) – No

Whether the research analyst or research entity or his associate or his relative has any other material conflict of interest at the time of publication of the research report or at the time of public appearance – No

Whether it or its associates have received any compensation from the subject company in the past twelve months – No

Whether it or its associates have managed or co-managed public offering of securities for the subject company in the past 12 months – No

Whether it or its associates have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months – No

Whether it or its associates have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months – No

Whether the subject company is or was a client during twelve months preceding the date of distribution of the research report and the types of services provided – No

Whether the research analyst has served as an officer, director or employee of the subject company – No

Whether the research analyst or research entity has been engaged in market making activity for the subject company – No